Published in Curr Med Chem on June 01, 2003
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Ferritin for the clinician. Blood Rev (2008) 1.46
The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A (2008) 1.35
The neglected significance of "antioxidative stress". Oxid Med Cell Longev (2012) 1.06
Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget (2015) 1.04
The antitumor activity of the fungicide ciclopirox. Int J Cancer (2010) 1.02
Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem (2011) 0.98
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell (2014) 0.91
Reactions of N-benzyloxycarbamate derivatives with stabilized carbon nucleophiles: a new synthetic approach to polyhydroxamic acids and other hydroxamate-containing mixed ligand systems. J Org Chem (2009) 0.89
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. J Biol Chem (2008) 0.85
Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents. Res Pharm Sci (2011) 0.82
Subcellular redistribution and mitotic inheritance of transition metals in proliferating mouse fibroblast cells. Metallomics (2013) 0.82
Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. PLoS One (2014) 0.82
Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition. Front Biol (Beijing) (2014) 0.81
miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl) (2015) 0.80
3,2-Hydroxypyridinone (3,2-HOPO) vinyl sulfonamide and acrylamide linkers: Aza-Michael addition reactions and the preparation of poly-HOPO chelators. Tetrahedron Lett (2013) 0.79
Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. Thorac Cancer (2014) 0.79
Restoring the secretory function of irradiation-damaged salivary gland by administrating deferoxamine in mice. PLoS One (2014) 0.78
The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient. Int J Nanomedicine (2014) 0.77
Theranostic Polyaminocarboxylate-Cyanine-Transferrin Conjugate for Anticancer Therapy and Near-Infrared Optical Imaging. ChemMedChem (2016) 0.75
Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin. Bosn J Basic Med Sci (2016) 0.75
CrMAPK3 regulates the expression of iron-deficiency-responsive genes in Chlamydomonas reinhardtii. BMC Biochem (2017) 0.75
Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular Ascorbate. Front Oncol (2014) 0.75
Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes. Inorg Chem (2017) 0.75
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Regulation of ferritin genes and protein. Blood (2002) 3.27
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
Iron and cancer: more ore to be mined. Nat Rev Cancer (2013) 2.40
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A (2010) 1.99
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging (2013) 1.82
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Iron chelators in cancer chemotherapy. Curr Top Med Chem (2004) 1.61
TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med (2005) 1.52
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
Ferritin for the clinician. Blood Rev (2008) 1.46
Demand for continuing medical education programs on cancer care among primary care physicians in North Carolina. N C Med J (2004) 1.46
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A (2009) 1.34
Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol (2002) 1.30
Ironing out cancer. Cancer Res (2011) 1.25
Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem (2002) 1.23
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Iron chelation in the biological activity of curcumin. Free Radic Biol Med (2006) 1.17
Excess capacity of the iron regulatory protein system. J Biol Chem (2007) 1.14
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode. Breast Cancer Res Treat (2010) 1.14
Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res (2003) 1.13
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol (2009) 1.10
Bioinformatics tools for cancer metabolomics. Metabolomics (2011) 1.10
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood (2005) 1.08
Photothermal response of human and murine cancer cells to multiwalled carbon nanotubes after laser irradiation. Cancer Res (2010) 1.05
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging (2010) 1.05
BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem (2009) 1.04
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst (2009) 1.02
A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell (2007) 1.01
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res (2005) 1.01
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol (2008) 1.01
Oxathiolene oxide synthesis via chelation-controlled addition of organometallic reagents to alkynols followed by addition of sulfur electrophiles and evaluation of oxathiolene oxides as anticarcinogenic enzyme inducers. Bioorg Med Chem (2005) 0.98
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol (2012) 0.98
The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials (2012) 0.97
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology (2006) 0.97
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
IRP2 regulates breast tumor growth. Cancer Res (2013) 0.94
Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem (2002) 0.94
Fluorinated graphene oxide; a new multimodal material for biological applications. Adv Mater (2013) 0.93
Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. Nanomedicine (Lond) (2011) 0.92
Serum levels of phytanic acid are associated with prostate cancer risk. Prostate (2005) 0.92
Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials (2011) 0.92
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate (2012) 0.89
Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One (2011) 0.89
Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J (2002) 0.89
Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev (2013) 0.89
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat (2010) 0.89
Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo. Biochem J (2006) 0.89
Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. Am J Manag Care (2008) 0.88
Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress. Free Radic Biol Med (2011) 0.88
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol (2004) 0.88
A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy (2014) 0.88
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2007) 0.87
A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Cancer Chemother Pharmacol (2005) 0.87
Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate (2012) 0.86